Inhibikase Therapeutics Inc. (IKT): What Does Valuation Ratios Tell Us?

0
5
BEPC Stock
BEPC Stock

Inhibikase Therapeutics Inc. (NASDAQ:IKT) saw an upside of 9.42% to $1.00 after adding $0.09 on Wednesday. The 5-day average trading volume is 1,293,604 shares of the company’s common stock. It has gained $1.1573 in the past week and touched a new high 4 times within the past 5 days. An average of 378,131 shares of the company has been traded in the last 20 days, and the 50-day average volume stands at 200,482.

IKT’s 1-month performance is 89.58% or $0.4850 on its low of $0.4500 reached on 12/27/22. The company’s shares have touched a 52-week low of $0.44 and high of $1.52, with the stock’s rally to the 52-week high happening on 01/25/23. YTD, IKT has achieved 82.00% or $0.4800 and has reached a new high 14 times. However, the current price is down -34.49% from the 52-week high price.


Will You Miss Out On This Growth Stock Boom?

A new megatrend in the fintech market is well underway. Mobile payments are projected to boom into a massive $12 trillion market by 2028. According to Motley Fool this growth stock could "deliver huge returns." Not only in the immediate future but also over the next decade. Especially since the man behind this company is a serial entrepreneur who has been wildly successful over the years.

And this is just one of our 5 Best Growth Stocks To Own For 2023.

Sponsored


Valuation Metrics

Moving on to other valuation ratios, the trailing price-to-sales (P/S) ratio is 357.12 while the price-to-book (PB) in the most recent quarter is 0.91.

Inhibikase Therapeutics Inc.’s quick ratio for the period ended June 29 was 8.70, with the current ratio over the same period at 8.70. The firm’s gross profit as reported stood at $17.87 million against revenue of $3.1 million.

Earnings Surprise

For the quarterly period ending June 29 this year, Inhibikase Therapeutics Inc.’s cash and short-term investments amounted to $20.75 million. Net income and sales went up compared to those figures reported in the previous quarter. Net income grew 0.45% to -$4.49 million, while revenue of -$4.64 million was -3.34% off the previous quarter. Analysts expected IKT to announce -$0.19 per share in earnings in its latest quarter, but it posted -$0.18, representing a 5.30% surprise. EBITDA for the quarter stood at more than -$4.51 million. Shareholders hold equity totaling $25.23 million.

Let’s look briefly at Inhibikase Therapeutics Inc. (IKT) price momentum from a technical analysis perspective. The 9-day relative strength index as at close on 24 January was 91.20% to suggest the stock is trending Overbought, with historical volatility in this time period at 101.53%.

The stock’s 5-day moving average is $0.7946, reflecting a +49.39% or $0.3240 change from its current price. IKT is currently trading +97.98% above its 20-day SMA, +2.13% above its 100-day SMA. However, the stock’s current price level is away from the SMA50 by +104.17% and SMA200 by-30.00%.

Stochastic %K and %D was 84.67% and 84.09% and the average true range (ATR) pointed at 0.1056. The RSI (14) points at 84.50%, while the 14-day stochastic is at 71.28% with the period’s ATR at 0.0919. The stock’s 9-day MACD Oscillator is pointing at 0.1579 and 0.2071 on the 14-day charts.

Analyst Ratings

Analysts offering their rating for IKT stock have a consensus rating for the stock as Hold. Currently, 0 brokerage advisors rate IKT as a “sell,”, while 1 advise that investors “Hold.” 0 analysts have rated the stock as underweight. 0 rates the stock as overweight while 0 have offered a “buy” rating.

What is IKT’s price target for the next 12 months?

Analysts have a consensus price target ranging from a low of $6.00 and a high of $6.00, with their median price target at $6.00. Looking at these predictions, the average price target given by analysts is for Inhibikase Therapeutics Inc. (IKT) stock is $6.00.

LEAVE A REPLY

Please enter your comment!
Please enter your name here